Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,320 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study - Attachment: Release.pdf
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing the presentation of clinical study abstracts at a scientific congress. It contains no financial results, no regulatory report attachments, no earnings figures, no board changes, no M&A or legal notices. It does not qualify as an Annual Report, Interim Report, Earnings Release, Investor Presentation, or any of the specific financial/transaction filings. As a general corporate announcement not fitting other categories, it falls under the fallback “Regulatory Filings” category (RNS).
2026-05-18 English
AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study
Regulatory Filings Classification · 65% confidence The document is a corporate press release announcing research abstracts presented at a medical conference (AUA 2026). It contains no financial statements, no earnings figures, no proxy materials, no management or board changes, and is not an investor slide deck. It is therefore a general announcement and falls under the fallback category “Regulatory Filings” (RNS).
2026-05-18 English
Photocure ASA: Results for the first quarter of 2026 - Attachment: Photocure_Q1_2026_report.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Report Q1 2026' and contains detailed financial data for the first quarter of 2026, including revenue, EBITDA, EBIT, net earnings, and segment breakdowns. It also includes management commentary, guidance for the full year 2026, and operational highlights. The presence of actual financial statements and substantive financial analysis for a period shorter than a full fiscal year clearly indicates this is a quarterly financial report. The length of the document (15,000 characters) and the detailed financial content confirm it is not merely an announcement or a summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-07 Norwegian
Photocure ASA: Results for the first quarter of 2026 - Attachment: Photocure_Q1_2026_presentation.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Photocure ASA 1st Quarter 2026 Results' and contains detailed financial and operational data for Q1 2026, including revenue figures, EBITDA, unit sales, regional performance, strategic initiatives, and market outlook. It includes forward-looking statements, detailed segment trends, and business updates. The length is substantial (15,000 characters) and it contains substantive financial data and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). It is not a brief announcement or a presentation only, but a comprehensive report on quarterly results. Q1 2026
2026-05-07 Norwegian
Photocure ASA: Results for the first quarter of 2026 - Attachment: Release.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed report of Photocure ASA's financial and operational results for the first quarter of 2026. It includes specific financial figures such as revenues, EBITDA, EBIT, cash position, and discusses strategic and regulatory updates. It mentions the quarterly period explicitly (Q1 2026) and provides substantive financial data and analysis, including growth expectations and operational highlights. The document also references a webcast and presentation related to the quarterly results. The length of the document (8363 characters) and the detailed financial content confirm it is a comprehensive quarterly financial report rather than a brief announcement or a presentation alone. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-07 Norwegian
Photocure ASA: Results for the first quarter of 2026
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Results for the first quarter of 2026' and contains detailed financial data such as revenues, EBITDA, EBIT, cash equivalents, and strategic updates. It includes forward-looking statements, operational highlights, and financial performance metrics for the quarter. The length of the document (8943 characters) and the presence of substantive financial data and analysis indicate it is a comprehensive financial report for a period shorter than a full fiscal year. The document also mentions a webcast and presentation related to the quarterly results, which is typical for an Interim/Quarterly Report. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-07 Norwegian

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.